122
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center

, , , , , , , , & ORCID Icon show all
Pages 369-376 | Published online: 28 May 2021

References

  • Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699. doi:10.1111/j.1538-7836.2007.02450.x PMID: 17367492.
  • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026
  • Pollak AW, McBane RD. Succinct review of the new VTE prevention and management guidelines. Mayo Clin Proc. 2014;89(3):394–408. doi:10.1016/j.mayocp.2013.11.015
  • Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016;2016(1):1–9. doi:10.1182/asheducation-2016.1.1
  • Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013(1):9–14. doi:10.1182/asheducation-2013.1.9
  • Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209–220. doi:10.1111/j.1365-2141.2009.08022.x
  • Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax. 2013;68(4):391–393. doi:10.1136/thoraxjnl-2012-202376
  • Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–164. doi:10.1007/s11239-015-1316-1
  • Connors JM, Longo DL. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177–1187. doi:10.1056/NEJMra1700365
  • Singh D, Natarajan A, Nand S, Mai HP. Genetics of hypercoagulable and hypocoagulable states. Neurosurg Clin N Am. 2018;29(4):493–501. doi:10.1016/j.nec.2018.06.002
  • Rybstein MD, DeSancho MT. Hypercoagulable states and thrombophilias: risks relating to recurrent venous thromboembolism. Semin Intervent Radiol. 2018;35(2):99–104. doi:10.1055/s-0038-1642037
  • Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010–2021. doi:10.1056/NEJMra1705454
  • Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–426. doi:10.1503/cmaj.080493
  • Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program. 2007;2007(1):127–135. doi:10.1182/asheducation-2007.1.127
  • Pruthi RK. Optimal utilization of thrombophilia testing. Int J Lab Hematol. 2017;39(Suppl 1):104–110. doi:10.1111/ijlh.12672
  • Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–526. doi:10.1016/S0140-6736(03)14111-6
  • Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352–2361. doi:10.1001/jama.293.19.2352
  • Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729–736. doi:10.1001/archinte.166.7.729
  • Campello E, Spiezia L, Adamo A, Simioni P. Thrombophilia, risk factors and prevention. Expert Rev Hematol. 2019;12(3):147–158. doi:10.1080/17474086.2019.1583555